Gabinet Lekarski-Bartosz Korczowski

Rzeszów 35302

1 studies enrolling now · 16 studies all time

What they study most

Celiac Disease, Clostridium Difficile Infection, Crohn Disease, Crohn's Disease, Moderately to Severely Active Crohn Disease, Ulcerative Colitis

Studies at this site

• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• ABTECT - Maintenance — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis — Completed
• Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis — Completed
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet — Completed
• Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD) — Stopped early
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease — Completed
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis — Completed
• BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity — Completed